Maxim Group Maintains MediWound(MDWD.US) With Buy Rating
Maxim Group analyst Michael Okunewitch maintains $MediWound(MDWD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 29.0% and a total average return of -15.8% over
MediWound Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/16/2024 34.94% HC Wainwright & Co. $28 → $28 Reiterates Buy → Buy 05/30/2024 34.94% HC Wainwright & Co.
MediWound Accelerates DFU Treatment With EIC Funds
Express News | Mediwound Announces €16.25 Million Funding From the European Innovation Council Accelerator Program
Express News | Mediwound Ltd : Maxim Group Raises Target Price to $30 From $25
Press Release: MediWound Announces EUR16.25 Million Funding From the European Innovation Council Accelerator Program
MediWound Announces EUR16.25 Million Funding from the European Innovation Council Accelerator Program Funds to be used for clinical development of EscharEx(R) to treat diabetic foot ulcers (DFUs)
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $28
H.C. Wainwright analyst Swayampakula Ramakanth maintains $MediWound(MDWD.US)$ with a buy rating, and maintains the target price at $28.According to TipRanks data, the analyst has a success rate of 34.
Analysts' Top Healthcare Picks: Checkpoint Therapeutics (CKPT), Mediwound (MDWD)
MediWound Announces €16.25 Million Funding From the European Innovation Council Accelerator Program
Funds to be used for clinical development of EscharEx to treat diabetic foot ulcers (DFUs) Award advances MediWound's DFU program and its future revenues four years ahead of original schedule YAVNE,
Express News | Mediwound Ltd - 50% of Prepayment in Cash, 50% in Form of Ordinary Shares of Co to Be Issued by Co to Teva
Express News | Mediwound Ltd - Under Amendment, Co Will Prepay Teva US$4 Mln as Final Payment Due From Company Under Agreement
Express News | Mediwound Ltd - Amendment to Settlement Agreement With Teva
MediWound Flat on Investment From Molylnecke
TD Cowen Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $25
TD Cowen analyst Josh Jennings maintains $MediWound(MDWD.US)$ with a buy rating, and maintains the target price at $25.According to TipRanks data, the analyst has a success rate of 53.2% and a total
Sector Update: Health Care Stocks Edge Higher Premarket Monday
Health care stocks were edging higher premarket Monday with the Health Care Select Sector SPDR Fund (XLV) up 0.5% and the iShares Biotechnology ETF (IBB) recently advancing by 0.4%.ASLAN
Buy Rating Affirmed for Mediwound: Strategic Alliances and Financial Infusions Signal Strong Market Position for EscharEx
MediWound Down 12% In Pre-market After Privately Placing 1.45 Mln Shares
Mölnlycke Invests $15M in MediWound to Enhance Wound Care Solutions
Mölnlycke Health Care, a world-leading MedTech company specialising in solutions for wound care and surgical procedures, announced today an investment of US $15m in MediWound Ltd. (NASDAQ:MDWD) (
Express News | Mölnlycke® Health Care Announces US $15M Investment in Next-Generation Enzymatic Therapeutics Company Mediwound Ltd
MediWound | 6-K: Report of foreign private issuer (related to financial reporting)